Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Adaptimmune Therapeutics (ADAP) stock
Learn how to easily invest in Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics plc is a biotechnology business based in the US. Adaptimmune Therapeutics shares (ADAP) are listed on the NASDAQ and all prices are listed in US Dollars. Adaptimmune Therapeutics employs 462 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Adaptimmune Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ADAP – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Adaptimmune Therapeutics stock price (NASDAQ: ADAP)Use our graph to track the performance of ADAP stocks over time.
Adaptimmune Therapeutics shares at a glance
|Latest market close||$5.03|
|52-week range||$3.55 - $10.93|
|50-day moving average||$4.19|
|200-day moving average||$5.15|
|Wall St. target price||$10.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.97|
Buy Adaptimmune Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Adaptimmune Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adaptimmune Therapeutics price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||14.06%|
|3 months (2021-04-28)||-12.37%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
Is Adaptimmune Therapeutics under- or over-valued?
Valuing Adaptimmune Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Adaptimmune Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Adaptimmune Therapeutics's PEG ratio
Adaptimmune Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.11. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Adaptimmune Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Adaptimmune Therapeutics financials
|Revenue TTM||$3.6 million|
|Gross profit TTM||$-87,610,000|
|Return on assets TTM||-25.39%|
|Return on equity TTM||-56.42%|
|Market capitalisation||$586.2 million|
TTM: trailing 12 months
Shorting Adaptimmune Therapeutics shares
There are currently 3.0 million Adaptimmune Therapeutics shares held short by investors – that's known as Adaptimmune Therapeutics's "short interest". This figure is 21.8% down from 3.8 million last month.
There are a few different ways that this level of interest in shorting Adaptimmune Therapeutics shares can be evaluated.
Adaptimmune Therapeutics's "short interest ratio" (SIR)
Adaptimmune Therapeutics's "short interest ratio" (SIR) is the quantity of Adaptimmune Therapeutics shares currently shorted divided by the average quantity of Adaptimmune Therapeutics shares traded daily (recently around 995064.11960133). Adaptimmune Therapeutics's SIR currently stands at 3.01. In other words for every 100,000 Adaptimmune Therapeutics shares traded daily on the market, roughly 3010 shares are currently held short.
However Adaptimmune Therapeutics's short interest can also be evaluated against the total number of Adaptimmune Therapeutics shares, or, against the total number of tradable Adaptimmune Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptimmune Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Adaptimmune Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0236% of the tradable shares (for every 100,000 tradable Adaptimmune Therapeutics shares, roughly 24 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Adaptimmune Therapeutics.
Find out more about how you can short Adaptimmune Therapeutics stock.
Adaptimmune Therapeutics share dividends
We're not expecting Adaptimmune Therapeutics to pay a dividend over the next 12 months.
Adaptimmune Therapeutics share price volatility
Over the last 12 months, Adaptimmune Therapeutics's shares have ranged in value from as little as $3.55 up to $10.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptimmune Therapeutics's is 2.1344. This would suggest that Adaptimmune Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc. , Alpine Immune Sciences, Inc. , and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc.
Stocks similar to Adaptimmune Therapeutics
Adaptimmune Therapeutics in the news
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Frequently asked questionsWhat percentage of Adaptimmune Therapeutics is owned by insiders or institutions?
Currently 0.111% of Adaptimmune Therapeutics shares are held by insiders and 83.28% by institutions. How many people work for Adaptimmune Therapeutics?
Latest data suggests 462 work at Adaptimmune Therapeutics. When does the fiscal year end for Adaptimmune Therapeutics?
Adaptimmune Therapeutics's fiscal year ends in December. Where is Adaptimmune Therapeutics based?
Adaptimmune Therapeutics's address is: 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX What is Adaptimmune Therapeutics's ISIN number?
Adaptimmune Therapeutics's international securities identification number is: US00653A1079 What is Adaptimmune Therapeutics's CUSIP number?
Adaptimmune Therapeutics's Committee on Uniform Securities Identification Procedures number is: 00653A107
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert